Taurine: a potential novel addition to the anti-systemic sclerosis weaponry

Arch Med Res. 2010 Jan;41(1):59-61. doi: 10.1016/j.arcmed.2009.11.005. Epub 2010 Jan 29.

Abstract

Vascular damage and immunological events leading to generation of fibrogenic fibroblasts are the main components of systemic sclerosis (SSc) pathogenesis. Superoxide anions play a role in endothelial damage by oxidizing circulating low-density lipoproteins. IL-1 plays a key role in the pathophysiology of SSc by inducing upregulation of adhesion molecules, inflammatory damage of the endothelium and tissue fibrosis. Elevated levels of proTh2 cytokines such as IL-6 in the early stages of SSc lead to enhanced fibroblast collagen production. Taurine, a semi-essential amino acid, is an antioxidant, inhibits the production of proinflammatory cytokines such as IL-1 and IL-6 and also inhibits production of TGF-beta, a major fibrogenic cytokine. Therefore, we conclude that taurine may be a novel addition to the treatment armamentarium of this disabling disorder.

Publication types

  • Review

MeSH terms

  • Humans
  • Scleroderma, Systemic / drug therapy*
  • Scleroderma, Systemic / physiopathology
  • Taurine / therapeutic use*

Substances

  • Taurine